Butterfly Medical – develops an innovative, implantable device for the treatment of Benign Prostatic Hyperplasia (BPH).
The Butterfly Medical device is a new generation of minimally invasive BPH treatment that does not require cutting or removing tissue.
Butterfly has CE Mark (Europe)
Butterfly is an investigational device in the USA, Limited by Federal (or United States) law to investigational use
Great early results in clinical trials
- Elegant, minimally invasive procedure
- Retraction of lateral lobes without the need to cut, burn or puncture tissue
- Fully reversible if needed
Interview with a Butterfly patient
BPH is the non-cancerous enlargement of the prostate, effecting affecting 50% of men above 60 and more than 70% of men above 70.
BPH symptoms have a significant effect on the quality of life.
Approximately 30 million men around the world experience some level of BPH symptoms and about 25% of those men will actively seek treatment.
company
Patrick brings more than 20 years of experience in the medtech industry.
Most recently, Patrick was the Business Unit VP, Urology and GYN at Olympus, leading the commercial launch of a BPH treatment in the US
Idan brings more than 18 year of commercial and business experience in the medical device industry.
Portfolio includes: FlowMedic (CEO), Abbott Vascular (marketing), MCS (marketing), Biotronik (sales)
Idan holds a BSc. in engineering and an MBA
One of Israel’s leading medical entrepreneurs.
Founded and invested in more than 20 startups.
Portfolio includes: Lumenis, Syneron, Rapid Medical, Tulip, RealView, Ventor
Adrian is a certified urologist with deep understanding of the BPH market.
A serial entrepreneur, Adrian brings years of experience in developing innovative medical technologies.
Portfolio includes: EON Surgical, Orthospace, Vibrant, Clip-Tip Medical, Saturix, Stepwise
James is a world renowned urologist. His las position was Vice Chair of Urology at the Cleveland Clinic.
James brings many years of experience in managing BPH, in day-to-day practice and clinical trials and in books and papers he co-authored
Vardit brings more than 15 years of experience in clinical and regulatory leadership positions, leading clinical and regulatory efforts in the US and various other countries.
Vardit holds a PhD in Biomedical Engineering
Over the last 20 years, Mr. Hovard has held multiple leadership roles at subsidiaries of Coloplast, a publicly-traded global medical device company. Most recently, he served as the President of Interventional Urology from 2011 to 2019. At Interventional Urology, Mr. Hovard operated in a CEO capacity leading approximately 900 employees across corporate development with complete oversight of R&D, operations/manufacturing, marketing, sales, human resources, finance and legal
Nayan Gregory Parekh is Founder and Managing Partner of New Rhein Healthcare Investors. Previously, Nayan ran the Mergers & Acquisitions department for Novartis AG and led the integration planning for Alcon, its largest acquisition.
Nayan holds a Ph.D. in Economics from Northwestern University.
Dr. Ivan Gergel has been Managing Partner and Chief Medical Officer at New Rhein since 2017. Previously, Ivan was CMO and Head of Drug Development for Nektar Therapeutics, Inc. and Executive VP and Chief Scientific Officer of Endo Health Solutions.
Ivan received his MD from the Royal Free Medical School, University of London, and his MBA from the Wharton School of the University of Pennsylvania.
news
This milestone reflects strong momentum as we advance toward our next stage of growth, following the completion of our pivotal trial.
This funding supports Butterfly’s mission to rethink the treatment of Benign Prostatic Hyperplasia (BPH) through a minimally invasive, tissue-sparing approach designed to restore quality of life for patients.
Butterfly Medical received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for the Butterfly Prostatic Retraction Device
This significant regulatory milestone follows Butterfly Medical’s completion of its 244-patient pivotal clinical trial and the submission of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA).
https://www.prnewswire.com/news-releases/butterfly-medical-achieves-eu-mdr-certification-for-next-generation-bph-treatment-302906797.html
Butterfly Medical participated in the American Urology Association annual conference, held this year in Washington DC.
The conference offered a great opportunity to meet with leading urologists and urology-focused companies and to learn of the recent developments in our space.
events
Butterfly Medical
Address
3 HaTnufa St., 7th floor, Yokneam Illit 2069207, Israel
office@butterfly-medical.com